COMUNICADO: Un estudio fase III del agente antitumoral Halaven® (eribulina) en sarcoma de tejidos blandos demuestra un incremento de

4. National Cancer Institute http://www.cancer.gov/cancertopics/pdq/treatment/adult-soft-tissue-sarcoma/HealthProfessional/page1 . Accessed February 2015

5. M. Schuichi, et al. Soft-Tissue Sarcoma Surveillance Counterpoint: Japan. Current Clinical Oncology. 2013; 233-234

6. H. Tsujii, et al. Carbon-Ion Radiotherapy: Principles, Practices, and Treatment Planning. Springer. 2014; (XII)312:237

7. R. Pollock. Soft Tissue Sarcomas: A Volume in the American Cancer Society Atlas of Clinical Oncology Series. 2012

8. Fletcher et al. World Health Organization Classification of Tumours of Soft Tissue and Bone (4th Edition). Lyon: IARC Press, 2013.

9. SPC Halaven (updated June 2014). Available at: http://www.medicines.org.uk/emc/medicine/24382/SPC/Halaven+0.44+mg+ml+solution+for+injection Accessed: February 2015

Fecha de preparación: marzo de 2015

Código de trabajo: Halaven-UK0402aCONTACTO: Consultas de los medios de comunicación : Eisai Europe Ltd,Cressida Robson/Jaypreet Dhillon , +44(0)7908 314 155/+44(0) 7951 078795, Cressida_Robson@eisai.net, Jay_Dhillon@eisai.net; Tonic LifeCommunications : Alex Davies/Nicola Lilley . +44(0) 7817 229010/+44 (0)7717 187 538, Alex.Davies@toniclc.com, Nicola.Lilley@toniclc.com